FDA Accelerates Organ-Preservation Path for Biomarker-Defined Rectal Cancer
The US Food and Drug Administration granted accelerated approval to dostarlimab-gxly for adults with previously untreated stage II or III mismatch repair–deficient or microsatellite instability–high locally advanced rectal cancer. The indication is unusually consequential…
